In a post hoc analysis of 7129 patients from five phase 3 STAMPEDE trials, PSA ≤0.2 ng/mL on hormone therapy predicted favourable survival, but 96-month survival for each PSA level differed by metastatic volume or nodal status; 24-week PSA associated most strongly.
Secondary analysisn = 7,129
Kayani et al. On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials